Dyanavel® XR (amphetamine) – New formulation approval
November 5, 2021, - Tris Pharma announced the FDA approval of Dyanavel XR (amphetamine) extended-release tablets, for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older.
Download PDF
